Galmed Pharmaceuticals (GLMD) stock rocketed higher on Thursday after the clinical-stage biopharmaceutical company announced the breakthrough development of a brain-penetrating new formulation of Aramchol. This is a major advancement for the company as crossing the blood-brain barrier is a necessity to create an effective treatment for Parkinson’s disease and other CNS diseases.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Galmed Pharmaceuticals said that the new Aramchol formulation was developed with the assistance of Barcode Nanotech. It is based on Barcode Nanotech’s proprietary platform that enables simultaneous screening of hundreds of different nanoparticle formulations in vivo. Additionally, AI tools were used to determine the most effective way to deliver the treatment to the brain. The company will achieve this with the sequestration of Aramchol in lipid nanoparticles that will be administered via subcutaneous injection.
Allen Baharaff, co-founder and CEO of Galmed Pharmaceuticals, said, “Based on our preliminary in-vitro data which demonstrated that Aramchol dose-dependently down-regulated αSyn-aggregation as well as indicating that the treatment was not associated with toxicity, we believe that treatment with Aramchol could prevent the pathophysiological cascade that leads to αSyn-aggregation which induces a chronic inflammatory state that is associated with PD disease progression and severity.”
Galmed Pharmaceuticals Stock Movement Today
Galmed Pharmaceuticals stock was up 89.57% in pre-market trading on Thursday, following a 9.18% rally yesterday. However, the shares have fallen 17.01% year-to-date and 50.6% over the past 12 months.
With today’s news came heavy trading of GLMD stock, as more than 64 million shares changed hands. For comparison, the company’s three-month average daily trading volume is about 84,000 shares.
Galmed Pharmaceuticals stock could have other catalysts on the horizon. The company said it intends to seek regulatory approval for Phase 1b/2 studies of Aramchol as a treatment for Parkinson’s disease in the second half of 2026.
Is Galmed Pharmaceuticals Stock a Buy, Sell, or Hold?
Turning to Wall Street, traditional analyst coverage of Galmed Pharmaceuticals is lacking. Fortunately, TipRanks’ AI analyst Spark has it covered. Spark rates GLMD as Neutral with a 55-cent price target. It cites “weak financial performance (no revenue, recurring losses, and negative free cash flow with declining equity)” as reasons for this stance.
